Cargando…
Pilot study of the safety and effect of adalimumab on pain, physical function, and musculoskeletal disease in mucopolysaccharidosis types I and II
Mucopolysaccharidosis I and II are lysosomal storage disorders that, despite treatment with hematopoietic cell transplantation (HCT) and/or enzyme replacement therapy (ERT), continue to cause significant skeletal abnormalities leading to pain, stiffness, physical dysfunction, and short stature. Tumo...
Autores principales: | Polgreen, Lynda E., Kunin-Batson, Alicia, Rudser, Kyle, Vehe, Richard K., Utz, Jeanine J., Whitley, Chester B., Dickson, Patricia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5238608/ https://www.ncbi.nlm.nih.gov/pubmed/28119823 http://dx.doi.org/10.1016/j.ymgmr.2017.01.002 |
Ejemplares similares
-
Association of somatic burden of disease with age and neuropsychological measures in attenuated mucopolysaccharidosis types I, II and VI
por: Ahmed, Alia, et al.
Publicado: (2016) -
Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
por: Lund, Troy C., et al.
Publicado: (2020) -
A longitudinal study of emotional adjustment, quality of life and adaptive function in attenuated MPS II
por: Shapiro, Elsa G., et al.
Publicado: (2016) -
Hypothyroidism in late-onset Pompe disease
por: Schneider, Joseph, et al.
Publicado: (2016) -
Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study
por: Nestrasil, Igor, et al.
Publicado: (2017)